The easiest way to email your members of CongressDonate Now
S.316 - Preserve Access to Affordable Generics Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
|Version||Word Count||Changes From Previous Version||Percent Change|
|Introduced in Senate||1,972||n/a||n/a|
|Reported in Senate||2,052||7 Show Changes Hide Changes||3%|
Key: changed or removed text inserted or modified text
Loading Bill Text
Rollover any line of text to comment and/or link to it.
January 17, 2007
Mr. KOHL (for himself, Mr. GRASSLEY, Mr. LEAHY, Mr. SCHUMER, and Mr. FEINGOLD, Mr. KENNEDY, and Mr. DURBIN) introduced the following bill; which was read twice and referred to the Committee on the JudiciaryCommentsClose CommentsPermalink
SECTION 1. SHORT TITLE.
SEC. 2. CONGRESSIONAL FINDINGS AND DECLARATION OF PURPOSES.
(4) consumers and the health care system would benefit from free and open competition in the pharmaceutical market and the removal of obstacles to the introduction of generic drugs;CommentsClose CommentsPermalink
(5) full and free competition in the pharmaceutical industry, and the full enforcement of antitrust law to prevent anticompetitive practices in this industry, will lead to lower prices, greater innovation, and inure to the general benefit of consumers.CommentsClose CommentsPermalink
(6) the Federal Trade Commission has determined that some brand name pharmaceutical manufacturers collude with generic drug manufacturers to delay the marketing of competing, low-cost, generic drugs;CommentsClose CommentsPermalink
(7) collusion by the brand name pharmaceutical manufacturers is contrary to free competition, to the interests of consumers, and to the principles underlying antitrust law;CommentsClose CommentsPermalink
(8) in 2005, 2 appellate court decisions reversed the Federal Trade Commission's long-standing position, and upheld settlements that include pay-offs by brand name pharmaceutical manufacturers to generic manufacturers designed to keep generic competition off the market;CommentsClose CommentsPermalink
(9) in the 6 months following the March 2005 court decisions, the Federal Trade Commission found there were three settlement agreements in which the generic received compensation and agreed to a restriction on its ability to market the product;CommentsClose CommentsPermalink
(10) the FTC found that more than 2/3 of the approximately ten settlement agreements made in 2006 include a pay-off from the brand in exchange for a promise by the generic company to delay entry into the market; andCommentsClose CommentsPermalink
(11) settlements which include a payment from a brand name manufacturer to a generic manufacturer to delay entry by generic drugs are anti-competitive and contrary to the interests of consumers.CommentsClose CommentsPermalink
(1) to enhance competition in the pharmaceutical market by prohibiting anticompetitive agreements and collusion between brand name and generic drug manufacturers intended to keep generic drugs off the market;CommentsClose CommentsPermalink
(3) to clarify the law to prohibit payments from brand name to generic drug manufacturers with the purpose to prevent or delay the entry of competition from generic drugs.CommentsClose CommentsPermalink
SEC. 3. UNLAWFUL COMPENSATION FOR DELAY.
`SEC. 28. UNLAWFUL INTERFERENCE WITH GENERIC MARKETING.
`(a) It shall be unlawful under this Act for any person, in connection with the sale of a drug product, to directly or indirectly be a party to any agreement resolving or settling a patent infringement claim which--CommentsClose CommentsPermalink
`(b) Nothing in this section shall prohibit a resolution or settlement of patent infringement claim in which the value paid by the NDA holder to the ANDA filer as a part of the resolution or settlement of the patent infringement claim includes no more than the right to market the ANDA product prior to the expiration of the patent that is the basis for the patent infringement claim.CommentsClose CommentsPermalink
`(1) The term `agreement' means anything that would constitute an agreement under section 1 of the Sherman Act (
`(2) The term `agreement resolving or settling a patent infringement claim' includes, any agreement that is contingent upon, provides a contingent condition for, or is otherwise related to the resolution or settlement of the claim.CommentsClose CommentsPermalink
`(6) The term `drug product' means a finished dosage form (e.g., tablet, capsule, or solution) that contains a drug substance, generally, but not necessarily, in association with 1 or more other ingredients, as defined in section 314.3(b) of title 21, Code of Federal Regulations.CommentsClose CommentsPermalink
`(B) a party owning or controlling enforcement of the patent listed in the Approved Drug Products With Therapeutic Equivalence Evaluations (commonly known as the `FDA Orange Book') in connection with the NDA; orCommentsClose CommentsPermalink
`(C) the predecessors, subsidiaries, divisions, groups, and affiliates controlled by, controlling, or under common control with any of the entities described in subclauses (i) and (ii) (such control to be presumed by direct or indirect share ownership of 50 percent or greater), as well as the licensees, licensors, successors, and assigns of each of the entities.CommentsClose CommentsPermalink
`(9) The term `patent infringement' means infringement of any patent or of any filed patent application, extension, reissue, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patents of addition and extensions thereof.CommentsClose CommentsPermalink
`(10) The term `patent infringement claim' means any allegation made to an ANDA filer, whether or not included in a complaint filed with a court of law, that its ANDA or ANDA product may infringe any patent held by, or exclusively licensed to, the NDA holder of the drug product.'.CommentsClose CommentsPermalink
SEC. 4. NOTICE AND CERTIFICATION OF AGREEMENTS.
(2) inserting before the period at the end the following: `; and (2) a description of the subject matter of any other agreement the parties enter into within 30 days of an entering into an agreement covered by subsection (a) or (b)'.CommentsClose CommentsPermalink
`(d) Certification- The Chief Executive Officer or the company official responsible for negotiating any agreement required to be filed under subsection (a), (b), or (c) shall execute and file with the Assistant Attorney General and the Commission a certification as follows: `I declare under penalty of perjury that the following is true and correct: The materials filed with the Federal Trade Commission and the Department of Justice under section 1112 of subtitle B of title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, with respect to the agreement referenced in this certification: (1) represent the complete, final, and exclusive agreement between the parties; (2) include any ancillary agreements that are contingent upon, provide a contingent condition for, or are otherwise related to, the referenced agreement; and (3) include written descriptions of any oral agreements, representations, commitments, or promises between the parties that are responsive to subsection (a) or (b) of such section 1112 and have not been reduced to writing.'.'.CommentsClose CommentsPermalink
SEC. 5. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD.
Section 505 of the Federal Food, Drug and Cosmetic Act (
SEC. 6. STUDY BY THE FEDERAL TRADE COMMISSION.
(a) Requirement for a Study- Not later than 180 days after the date of enactment of this Act and pursuant to its authority under section 6(a) of the Federal Trade Commission Act (
(3) the prevalence in the pharmaceutical industry of other anticompetitive agreements among competitors or other practices that are contrary to the antitrust laws, and the impact of such agreements or practices on competition in the pharmaceutical market during the last 5 years.CommentsClose CommentsPermalink
(b) Consultation- In conducting the study required under this section, the Federal Trade Commission shall consult with the Antitrust Division of the Department of Justice regarding the Justice Department's findings and investigations regarding anticompetitive practices in the pharmaceutical market, including criminal antitrust investigations completed by the Justice Department with respect to practices or conduct in the pharmaceutical market.CommentsClose CommentsPermalink
(c) Requirement for a Report- Not later than 1 year after the date of enactment of this Act, the Federal Trade Commission shall submit a report to the Judiciary Committees of Senate and House of Representatives, and to the Department of Justice regarding the findings of the study conducted under subsection (a). This report shall contain the Federal Trade Commission's recommendation as to whether any amendment to the antitrust laws should be enacted to correct any substantial lessening of competition found during the study.CommentsClose CommentsPermalink
(d) Federal Agency Consideration- Upon receipt of the report required by subsection (c), the Attorney General or the Chairman of the Federal Trade Commission, as appropriate, shall consider whether any additional enforcement action is required to restore competition or prevent a substantial lessening of competition occurring as a result of the conduct or practices that were the subject of the study conducted under subsection (b).CommentsClose CommentsPermalink
SEC. 7. AUTHORIZATION OF APPROPRIATIONS.
Vote on This Bill
OC Blog Articles Related To This Bill
- Will Government Employees Publicly Oppose #FreeTHOMAS? Jun 05, 2012
- Yes, let's stride towards an open VCS for legislation (or, GitHub for laws on OC) May 23, 2012
- Anti-Web Censorship Bill Protest from Our Perspective at OC Feb 08, 2012
- SOPA/PIPA Dead ...For Now. Jan 20, 2012
- Help Us Whip #PIPA Jan 13, 2012